Measuring the cost-effectiveness of treating rectovaginal and vesicovaginal fistulas: A multicenter global study by the Fistula Foundation

被引:1
|
作者
Rajagopal, Keerthana [1 ,2 ]
Pollaczek, Lindsey [1 ]
Chu, Jesse [1 ]
Mann, Hannah [1 ]
机构
[1] Fistula Fdn, San Jose, CA USA
[2] Fistula Fdn, 1700 The Alameda 300, San Jose, CA 95126 USA
关键词
cost-effectiveness; disability-adjusted life-years; rectovaginal fistula; resource allocation; vesicovaginal fistula; OBSTETRIC FISTULA;
D O I
10.1002/ijgo.15502
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveSurgery for obstetric fistula is a highly effective treatment to restore continence and improve quality of life. However, a lack of data on the cost-effectiveness of this procedure limits prioritization of this essential treatment. This study measures the effectiveness of fistula surgeries using disability-adjusted life years (DALYs) averted.MethodsIn 2021 and 2022, the Fistula Foundation funded 20 179 fistula surgeries and related procedures at 143 hospitals among 27 countries. We calculated DALYs averted specifically for vesicovaginal fistula and rectovaginal fistula procedure types (n = 13 235 surgeries) by using disability weights from the 2019 Global Burden of Disease study. We based cost calculations on direct treatment expenses, including medical supplies, health provider fees, and preoperative and postoperative care. We measured effectiveness using data on the risk of permanent disability, country-specific average life spans, and treatment outcomes.ResultsThe total treatment cost was $7.6 million, and a total of 131 433 DALYs were averted. Thus, the cost per DALY averted-the cost to restore 1 year of healthy life-was $58. For this analysis, we took a cautious approach and weighted only surgeries that resulted in a closed fistula with restored continence. We calculated DALYs averted by country. Limitations of the study include data entry errors inherent in patient logs and lack of long-term outcomes.ConclusionThe current study demonstrates that obstetric fistula surgery, along with having a significant positive impact on maternal health outcomes, is highly cost-effective in comparison with other interventions. The study therefore highlights the benefits of prioritizing fistula treatment as part of the global agenda for maternal health care. Obstetric fistula treatment is highly cost-effective. The current study highlights the benefits of prioritizing fistula treatment as part of the global agenda for maternal health care.
引用
收藏
页码:480 / 486
页数:7
相关论文
共 50 条
  • [1] Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
    Lakdawalla, D.
    Penrod, J.
    Maclean, R.
    Humphrey, J. S.
    Seabury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] Treating miscarriages: a randomised study of cost-effectiveness in medical or surgical choice
    Niinimaki, M.
    Karinen, P.
    Hartikainen, A-L
    Pouta, A.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2009, 116 (07) : 984 - 990
  • [3] Cephalic arch stenosis: angioplasty to preserve a brachiocephalic fistula or new brachiobasilic fistula?: a cost-effectiveness study
    Aitken, Emma L.
    Jackson, Andrew J.
    Hameed, Harris
    Chandramohan, Mohan
    Kasthuri, Ram
    Kingsmore, David B.
    RENAL FAILURE, 2014, 36 (10) : 1550 - 1558
  • [4] Treating Miscarriages: A Randomized Study of Cost-Effectiveness in Medical or Surgical Choice EDITORIAL COMMENT
    Niinimaki, M.
    Karinen, P.
    Hartikainen, A. -L.
    Pouta, A.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2009, 64 (10) : 658 - 659
  • [5] Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: A cohort study in the Philippines
    Tupasi, Thelma E.
    Gupta, Rajesh
    Quelapio, Ma Imelda D.
    Orillaza, Ruth B.
    Mira, Nona Rachel
    Mangubat, Nellie V.
    Belen, Virgil
    Arnisto, Nida
    Macalintal, Lualhati
    Arabit, Michael
    Lagahid, Jaime Y.
    Espinal, Marcos
    Floyd, Katherine
    PLOS MEDICINE, 2006, 3 (09) : 1587 - 1596
  • [6] Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
    Guzauskas, Gregory F.
    Pollom, Erqi L.
    Stieber, Volker W.
    Wang, Bruce C. M.
    Garrison, Louis P., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 1006 - 1013
  • [7] Cost-Effectiveness of Hospice Palliative Care for Patients With Cancer and Family Caregivers: A Multicenter Study in Kazakhstan
    Salikhanov, Islam
    Kunirova, Gulnara
    Aitbaeva, Aliya
    Crape, Byron
    Wieser, Simon
    Katapodi, Maria
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 69 - 76
  • [8] Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients
    Liu, Gordon
    Huang, Zhiyong
    Xin, Qian
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [9] Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis - a multicenter randomized controlled study
    Mateti, Uday Venkat
    Nagappa, Anantha Naik
    Attur, Ravindra Prabhu
    Nagaraju, Shankar Prasad
    Rangaswamy, Dharshan
    POSTGRADUATE MEDICINE, 2018, 130 (07) : 621 - 626
  • [10] Cost-effectiveness of Losartan versus Atenolol in treating hypertension - An analysis of the LIFE study from a Swiss perspective
    Szucs, TD
    Burnier, M
    Erne, P
    CARDIOVASCULAR DRUGS AND THERAPY, 2004, 18 (05) : 391 - 397